SL-401: Phase I/II data

Data from 15 evaluable patients in an open-label, U.S. Phase I/II trial showed that SL-401 had led to a dose-limiting toxicity (DLT) of capillary leak syndrome ( CLS) in 2 patients with BPDCN. A grade...